In RCC, Mcl-1 expression is linked to TNF-alpha-related apoptosis-inducing ligand (TRAIL) resistance, and sorafenib has been shown to reduce both expression of Mcl-1 and TRAIL resistance (71). This evidence concerns the gene MCL1 and renal cell carcinoma.